Phosphodiesterase-5 inhibitors for the treatment of secondary Raynaud's phenomenon: Systematic review and meta-analysis of randomised trials

Annals of the Rheumatic Diseases

Volumn 72, Issue 10, 2013, Pages 1696-1699

  Roustit, Matthieu ^a,b   Blaise, Sophie ^a,b   Allanore, Yannick ^c   Carpentier, Patrick H ^b   Caglayan, Evren ^d   Cracowski, Jean Luc ^a,b  

^a University Grenoble Alpes   (France)

^b GRENOBLE UNIVERSITY HOSPITAL   (France)

^c Université Paris Descartes ^*  (France)

^d UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; PHOSPHODIESTERASE V INHIBITOR; PLACEBO; SILDENAFIL; TADALAFIL; VARDENAFIL;

ADD ON THERAPY; CONTROLLED STUDY; CROSSOVER PROCEDURE; DISEASE ACTIVITY; DISEASE DURATION; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; HUMAN; LIMB ISCHEMIA; META ANALYSIS; PARALLEL DESIGN; PRIORITY JOURNAL; QUALITY CONTROL; RANDOMIZED CONTROLLED TRIAL; RAYNAUD CONDITION SCORE; RAYNAUD PHENOMENON; REVIEW; SCORING SYSTEM; SYSTEMATIC REVIEW; TREATMENT RESPONSE;

CARDIOVASCULAR DISEASE; OUTCOMES RESEARCH; SYSTEMIC SCLEROSIS;

CARBOLINES; HUMANS; IMIDAZOLES; PHOSPHODIESTERASE 5 INHIBITORS; PIPERAZINES; PURINES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RAYNAUD DISEASE; SULFONES; TREATMENT OUTCOME; TRIAZINES;

EID: 84883765672     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/annrheumdis-2012-202836     Document Type: Review

References (14)

1. Wigley FM. Clinical practice. Raynaud's phenomenon. N Engl J Med 2002;347:1001-8.
2. Thompson AE, Shea B, Welch V, et al. Calcium-channel blockers for Raynaud's phenomenon in systemic sclerosis. Arthritis rheum 2001;44:1841-7. (Pubitemid 32758232)
3. Kowal-Bielecka O, Landewé R, Avouac J, et al. EULAR recommendations for the treatment of systemic sclerosis: a report from the EULAR Scleroderma Trials and Research group (EUSTAR). Ann rheum dis 2009;68:620-8.
4. De LaVega AJ, Derk CT. Phosphodiesterase-5 inhibitors for the treatment of Raynaud's: a novel indication. Expert Opin Investig Drugs 2009;18:23-9.
5. Allanore Y. Phosphodiesterase 5 inhibitors in vascular systemic disorders. Joint Bone Spine 2012;79:338-40.
6. Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ 2009;339:b2700.
7. Elbourne DR, Altman DG, Higgins JP, et al. Meta-analyses involving cross-over trials: methodological issues. Int J Epidemiol 2002;31:140-9. (Pubitemid 34284916)
8. Schiopu E, Hsu VM, Impens AJ, et al. Randomized placebo-controlled crossover trial of tadalafil in Raynaud's phenomenon secondary to systemic sclerosis. J rheum 2009;36:2264-8.
9. Caglayan E, Axmann S, Hellmich M, et al. Vardenafil for the treatment of Raynaud phenomenon: a randomized, double-blind, placebo-controlled crossover study. Arch Intern Med 2012;172:1182-4.
10. Fries R, Shariat K, von Wilmowsky H, et al. Sildenafil in the treatment of Raynaud's phenomenon resistant to vasodilatory therapy. Circulation 2005;112:2980-5. (Pubitemid 41612301)
11. Shenoy PD, Kumar S, Jha LK, et al. Efficacy of tadalafil in secondary Raynaud's phenomenon resistant to vasodilator therapy: a double-blind randomized cross-over trial. Rheumatology (Oxford) 2010;49:2420-8.
12. Herrick AL, van den Hoogen F, Gabrielli A, et al. Modified-release sildenafil reduces Raynaud's phenomenon attack frequency in limited cutaneous systemic sclerosis. Arthritis Rheum 2011;63:775-82.
13. Agarwal V, Ghosh P, Sharma A, et al. Efficacy of tadalafil in Raynaud's phenomenon secondary to systemic sclerosis: a double-blind randomized placebo-controlled parallel group multicentric study (abstract). Arthritis Rheum 2010;62(Suppl 10):2086.
14. Khanna PP, Maranian P, Gregory J, et al. The minimally important difference and patient acceptable symptom state for the Raynaud's condition score in patients with Raynaud's phenomenon in a large randomised controlled clinical trial. Ann rheum dis 2010;69:588-91.